DIAMYD MEDICAL AB (PUBL) Inactive Instrument
Diamyd Medical AB (publ) Stock Nasdaq Stockholm
Equities
SE0005162880
Biotechnology & Medical Research
| Sales 2024 * | 3M 274K 375K | Sales 2025 * | 3M 274K 375K | Capitalization | 1.13B 103M 141M |
|---|---|---|---|---|---|
| Net income 2024 * | -133M -12.14M -16.61M | Net income 2025 * | -165M -15.07M -20.61M | EV / Sales 2024 * | 330 x |
| Net cash position 2024 * | 139M 12.69M 17.36M | Net cash position 2025 * | 30M 2.74M 3.75M | EV / Sales 2025 * | 366 x |
| P/E ratio 2024 * |
-8.27
x | P/E ratio 2025 * |
-6.67
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Diamyd Medical AB (publ)
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 16-04-09 |
| Founder | 83 | 95-12-31 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 09-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 83 | 95-12-31 | |
| Director/Board Member | 63 | 11-12-31 | |
| Director/Board Member | 52 | 21-04-27 |
Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
Calendar
2024-06-25
- Q3 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
